Syros pharmaceuticals, inc. (SYRS)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Operating activities
Net loss

-76,203

-75,438

-73,741

-69,685

-64,277

-62,279

0

0

0

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

0

0

-48,670

-

0

0

0

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization

2,682

2,521

2,118

1,944

1,733

1,604

1,562

1,545

1,550

1,527

1,475

1,399

1,334

1,273

0

0

0

Amortization of financing right-of-use asset

251

201

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Gain on disposal of fixed assets and modification of lease

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

10,419

9,839

8,256

7,404

6,793

6,610

6,248

5,819

5,231

4,419

3,878

4,464

4,456

4,234

0

0

0

Net amortization of premiums and discounts on marketable securities

702

949

1,059

1,069

869

642

409

230

178

102

0

0

0

-

-

-

-

Amortization of debit-discount and accretion of deferred debt costs

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

583

783

569

-573

-177

500

649

916

-24

-131

-361

-368

368

508

0

0

0

Accounts receivable

0

-

-

-

-

-

-

-

-

-867

0

0

0

-

-

-

-

Contract assets

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other long-term assets

0

-

-9

26

51

34

40

13

380

365

0

0

0

-

-

-

-

Accounts payable

1,043

1,493

611

347

840

888

805

-82

-641

141

-2,125

232

730

-404

0

0

0

Accrued expenses

-1,967

-3,576

60

274

-106

4,191

4,213

3,766

4,938

3,533

3,065

1,288

1,071

3,685

0

0

0

Deferred revenue

17,728

18,176

-2,367

-2,222

-2,134

10,202

11,095

11,508

11,882

-550

0

0

0

-

-

-

-

Proceeds for tenant improvement incentive from landlord

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease asset and liabilities

-1,878

-1,365

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent and lease incentive

-

-

-

-

-

-355

-346

-337

-328

-320

-310

-301

-293

-284

0

0

0

Net cash provided by (used in) operating activities

-39,680

-60,253

-63,462

-62,263

-58,242

-40,315

-37,070

-36,577

-34,309

-44,729

0

0

0

-

-

-

-

Investing activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Purchases of property and equipment

13,844

12,638

4,676

3,127

1,823

1,384

1,256

281

577

821

1,068

1,203

1,193

2,322

0

0

0

Purchases of marketable securities

-

108,206

132,974

127,918

127,920

96,768

0

0

0

-

-

-

-

-

-

-

-

Maturities of marketable securities

124,000

109,000

129,000

119,000

102,500

87,500

42,500

44,500

39,501

27,000

0

0

0

-

-

-

-

Net cash provided by (used in) investing activities

35,698

-11,734

-8,650

-12,036

-27,234

-10,643

-30,749

1,958

-5,332

-15,591

0

0

0

-

-

-

-

Financing activities
Payments on financing and capital lease obligations

223

205

151

98

46

50

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Payments on capital lease obligations

-

-

-

-

-

-

-

-

-

-

165

163

159

135

0

0

0

Proceeds from issuance of common stock through employee benefit plans

308

211

190

146

387

626

1,368

1,568

1,872

1,799

0

0

0

-

-

-

-

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

39,813

0

0

0

Proceeds from issuance of common stock through at-the-market sales agreement, net of issuance costs

0

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Proceeds from term loan, net of issuance costs

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of offering costs

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

0

0

Net cash provided by (used in) financing activities

97,798

65,990

65,038

65,377

16,802

69,084

69,639

69,281

85,976

33,937

0

0

0

-

-

-

-

Increase (decrease) in cash, cash equivalents and restricted cash

93,816

-5,997

-7,074

-8,922

-68,674

18,126

1,820

34,662

46,335

-26,383

0

0

0

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Supplemental disclosure of cash flow information:
Cash paid for interest

295

72

53

32

9

2

2

4

7

9

0

0

0

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Non-cash investing and financing activities:
Property and equipment received but unpaid as of period end

2,326

1,565

4,964

1,265

492

268

211

144

135

143

282

283

167

349

0

0

0

Assets acquired under financing lease

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred financing costs incurred but unpaid as of period end

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering costs incurred but unpaid as of period end

-65

23

0

0

0

-

-

-25

55

13

0

0

0

-

-

0

0